Menveo new single-vial approve by US FDA

17th Oct 2022 07:00

RNS Number : 0177D GSK PLC 17 October 2022 160

Issue: 17 October 2022, Lonon UK

160

US FDA approves Menveo in a new single-vial presentation to help prevent isease cause by meningococcal bacteria serogroups A, C, Y, an W

160

183 160 Single-vial presentation option removes the nee for reconstitution of Menveo before use in iniviuals 10 through years of age.

160

160160

GSK plc (LSE/NYSE: GSK) toay announce that the US Foo an Drug Aministration (FDA) has approve a new presentation of Menveo [Meningococcal (Groups A, C, Y, an W-13) Oligosaccharie Diptheria CRM197 Conjugate Vaccine] for iniviuals age 10 to years to help prevent invasive meningococcal isease cause by Neisseria meningitiis serogroups A, C, Y, an W. The Menveo one-vial presentation now comes in a reay to use single vial giving healthcare proviers a more convenient option. The Menveo one-vial presentation will initially be available to US feeral customers, with broaer availability anticipate in mi-2023.

160

Invasive meningococcal isease (IMD), known as meningitis, is an uncommon but serious illness that can cause life-threatening complications or even eath.1 IMD is cause by Neisseria meningitiis, with the majority of cases cause by serogroups (A, B, C, W, Y) in most of the worl.1 Among those who contract meningitis, one in ten will ie, espite treatment, sometimes in as little as 24 hours.1 One in five (up to 20%) of meningitis survivors suffer long-term consequences, such as brain amage, amputations, hearing loss an nervous system problems.1

160

Roger Connor, Presient, Vaccines an Global Health, GSK, sai: "Outbreaks of this angerous isease continue to occur, impacting families, health systems an society. This FDA approval of Menveo one-vial presentation offers greater convenience to healthcare proviers to help prevent this isease in at-risk populations in the Unite States."

160

The original two-vial presentation of Menveo requiring reconstitution, was approve by the FDA in 2010 an remains available for use in iniviuals from two months to years of age.

160

About Menveo

The Menveo vaccine (supplie in a two-vial presentation) for meningococcal groups A, C, Y, an W has been approve in over 60 countries, with more than 72 million oses istribute worlwie since 2010. It offers extensive evience of immunogenicity an a well-characterise safety profile. Menveo oes not prevent Neisseria meningitiis serogroup B infections.

160

The US Prescribing Information is available here.

160

Important Safety Information for Menveo in the US

160

The following is base on the US Prescribing Information for Menveo. Please consult the full Prescribing Information for all the labele safety information.

160

8226

Do not aminister Menveo to iniviuals with a severe allergic reaction (e.g., anaphylaxis) to a previous ose of Menveo, to any component of this vaccine, or to any other iphtheria toxoi-containing vaccine.

8226

Appropriate meical treatment must be available shoul an acute allergic reaction, incluing an anaphylactic reaction, occur following aministration of Menveo.

8226

Syncope (fainting) has occurre in association with aministration of Menveo. Proceures shoul be in place to avoi injury from fainting.

8226

Some iniviuals with altere immunocompetence, incluing some iniviuals receiving immunosuppressant therapy, may have reuce immune responses to Menveo.

8226

Persons with certain complement eficiencies an persons receiving treatment that inhibits terminal complement activation (for example, eculizumab) are at increase risk for invasive isease cause by N. meningitiis, incluing invasive isease cause by serogroups A, C, Y, an W, even if they evelop antiboies following vaccination with Menveo.

8226

Guillain-Barr233 synrome (GBS) has been reporte in temporal relationship following aministration of another US-license meningococcal quarivalent polysaccharie conjugate vaccine. The ecision to aminister Menveo to iniviuals with a history of GBS shoul take into account the expecte benefits an potential risks.

8226

Apnea following intramuscular vaccination has been observe in some infants born prematurely. A ecision about when to aminister Menveo to an infant born prematurely shoul be base on consieration of the iniviual infant's meical status an the potential benefits an possible risks of vaccination.

8226

Common solicite averse reactions among chilren initiating vaccination: at 2 months of age an receiving the 4-ose series were tenerness an erythema at injection site, irritability, sleepiness, persistent crying, change in eating habits, vomiting, an iarrhea at 7 months through 23 months of age an receiving the 2-ose series were tenerness an erythema at injection site, irritability, sleepiness, persistent crying, change in eating habits, an iarrhea at 2 through 10 years of age who receive Menveo were injection site pain, erythema, irritability, inuration, sleepiness, malaise, an heaache. Common solicite averse reactions among aolescents an aults age 11 through years who receive a single ose of Menveo were pain at the injection site, heaache, myalgia, malaise, an nausea. Across all age groups, some events were severe. Similar rates of solicite averse reactions among aolescents an aults were observe following a single booster ose.

8226

In two clinical stuies, there were no notable ifferences in frequency an severity of solicite averse reactions in iniviuals who receive Menveo one-vial presentation compare to iniviuals who receive the 2-vial presentation.

8226

Vaccination with Menveo may not result in protection in all vaccine recipients.

160

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, an talent to get ahea of isease together. Fin out more at gsk.com/company

160

GSK enquiries

Meia:

Tim Foley

+44 (0) 20 8047 02

(Lonon)

Simon Moore

+44 (0) 20 8047 02

(Lonon)

Alison Hunt

+1 40 742 3391

(Washington DC)

160

160

Investor Relations:

Nick Stone

+44 (0) 7717 618834

(Lonon)

James Dowell

+44 (0) 20 8047 2406

(Lonon)

Mick Reaey

+44 (0) 7990 33963

(Lonon)

Josh Williams

+44 (0) 738 41719

(Lonon)

Jeff McLaughlin

+1 21 71 7002

(Philaelphia)

Frannie DeFranco

+1 21 71 48

(Philaelphia)

160

Cautionary statement regaring forwar-looking statements

GSK cautions investors that any forwar-looking statements or projections mae by GSK, incluing those mae in this announcement, are subject to risks an uncertainties that may cause actual results to iffer materially from those projecte. Such factors inclue, but are not limite to, those escribe in the Company's Annual Report on Form 20-F for 2021, GSK's Q2 Results for 2022 an any impacts of the COVID-19 panemic.

160

Registere in Englan Wales:

No. 3888792

160

Registere Office:

980 Great West Roa

Brentfor, Milesex

TW8 9GS

160

References

[1]. 160 160 160Centers for Disease Control an Prevention. Vaccine Information Statements. Available at: Meningococcal Vaccine Information Statement | CDC.160

160 160 160 160 160Accesse October 2022.

160

160

160

160

160

160

160

160

160

160

160

160

160

---

160

This information is provie by RNS, the news service of the Lonon Stock Exchange. RNS is approve by the Financial Conuct Authority to act as a Primary Information Provier in the Unite Kingom. Terms an conitions relating to the use an istribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.RNS may use your IP aress to confirm compliance with the terms an conitions, to analyse how you engage with the information containe in this communication, an to share such analysis on an anonymise basis with others as part of our commercial services. For further information about how RNS an the Lonon Stock Exchange use the personal ata you provie us, please see our Privacy Policy.160 END160160REAEAKEKFSSAFFA

---

Related Shares:

Glaxosmithkline